Fig. 7: DHC sustains the contractile phenotype of rat VSMCs by upregulating spectrin alpha, erythrocytic 1 (Spta1) expression. | Acta Pharmacologica Sinica

Fig. 7: DHC sustains the contractile phenotype of rat VSMCs by upregulating spectrin alpha, erythrocytic 1 (Spta1) expression.

From: Dehydrocorydaline maintains the vascular smooth muscle cell contractile phenotype by upregulating Spta1

Fig. 7

a–c Rat VSMCs were treated with DMSO or 100 μM DHC for 24 h. a FPKM values of Spta1 from RNA-seq analysis (n = 3). b Detection of Spta1 mRNA level using RT-qPCR (n = 3). c Detection of SPTA1 protein level by Western blotting (n = 3). d, e Rat VSMCs were transfected with siNC or siSpta1 for 24 h and then treated with DMSO or 100 μM DHC for 24 h. d mRNA levels of contractile markers (Myh11, Sm22α, and Acta2) were assessed using RT-qPCR (n = 4). e Protein levels of contractile markers (Cnn1 and SM-MHC) were detected by Western blotting (n = 7). f Expression of α-SMA (green) in rat VSMCs was determined by immunofluorescence, with DAPI (blue) indicating the nucleus (n = 4, scale = 50 μm). Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, analyzed using unpaired t-tests (a to c) and one-way ANOVA (d to f).

Back to article page